Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin

BMC Medicine

Volumn 6, Issue , 2008, Pages

  Kolanczyk, Mateusz ^a,b,c   Kühnisch, Jirko ^b   Kossler, Nadine ^a,b   Osswald, Monika ^a,b   Stumpp, Sabine ^b   Thurisch, Boris ^a,b   Kornak, Uwe ^a,b   Mundlos, Stefan ^a,b,d  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c In Silico Miners   (Poland)

^d Berlin Brandenburg Center for Regenerative Therapies   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHACRYLIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PARAFFIN; TRANSCRIPTION FACTOR RUNX2; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEMINERALIZATION; BONE DYSPLASIA; BONE INJURY; BONE REMODELING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EXTRACELLULAR MATRIX; FEMALE; FIBROCARTILAGE; GENE EXPRESSION REGULATION; IN SITU HYBRIDIZATION; MALE; MOUSE; MOUSE MUTANT; NEUROFIBROMATOSIS; NONHUMAN; OSSIFICATION; SYSTEMIC THERAPY; ANIMAL; C57BL MOUSE; CHONDRODYSPLASIA; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; TIBIA;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; FEMALE; IN SITU HYBRIDIZATION; LOVASTATIN; MALE; MICE; MICE, INBRED C57BL; NEUROFIBROMATOSIS 1; OSTEOCHONDRODYSPLASIAS; TIBIA;

EID: 49949110162     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-6-21     Document Type: Article

References (33)

1. Hermanns-Sachweh B Senderek J Alfer J Klosterhalfen B Buttner R Fuzesi L Weber M Vascular changes in the periosteum of congenital pseudarthrosis of the tibia Pathol Res Pract 2005, 201(4):305-312. 10.1016/ j.prp.2004.09.013 15991837
2. Stevenson DA Birch PH Friedman JM Viskochil DH Balestrazzi P Boni S Buske A Korf BR Niimura M Pivnick EK Schorry EK Short MP Tenconi R Tonsgard JH Carey JC Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1 Am J Med Genet 1999, 84(5):413-419. 10.1002/(SICI)1096-8628(19990611)84:5<413::AID-AJMG5>3.0.CO;2-1 10360395
3. Stevenson DA Zhou H Ashrafi S Messiaen LM Carey JC D'Astous JL Santora SD Viskochil DH Double inactivation of NF1 in tibial pseudarthrosis Am J Hum Genet 2006, 79(1):143-148. 1474128 16773574 10.1086/504441
4. Kolanczyk M Kossler N Kuhnisch J Lavitas L Stricker S Wilkening U Manjubala I Fratzl P Sporle R Herrmann BG Parada LF Kornak U Mundlos S Multiple roles for neurofibromin in skeletal development and growth Hum Mol Genet 2007, 16(8):874-886. 10.1093/hmg/ddm032 17317783
5. Campbell TM Wong WT Mackie EJ Establishment of a model of cortical bone repair in mice Calcif Tissue Int 2003, 73(1):49-55. 10.1007/ s00223-002-2120-4 14506954
6. Song SJ Pagel CN Campbell TM Pike RN Mackie EJ The role of protease-activated receptor-1 in bone healing Am J Pathol 2005, 166(3):857-868. 1602347 15743797
7. Sakamoto A Yoshida T Yamamoto H Oda Y Tsuneyoshi M Iwamoto Y Congenital pseudarthrosis of the tibia: Analysis of the histology and the NF1 gene J Orthop Sci 2007, 12:4 361-365. 10.1007/s00776-007-1142-1 17657556
8. Kuorilehto T Kinnunen P Nissinen M Alanne M Leskela HV Lehenkari P Peltonen J Vasculopathy in two cases of NF1-related congenital pseudarthrosis Pathol Res Pract 2006, 202(9):687-690. 10.1016/ j.prp.2006.03.006 16735097
9. Khanzada UK Pardo OE Meier C Downward J Seckl MJ Arcaro A Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling Oncogene 2006, 25(6):877-887. 10.1038/sj.onc.1209117 16170339
10. Morgan MA Sebil T Aydilek E Peest D Ganser A Reuter CW Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells Br J Haematol 2005, 130(6):912-925. 10.1111/j.1365-2141.2005.05696.x 16156861
11. Ghittoni R Patrussi L Pirozzi K Pellegrini M Lazzerini PE Capecchi PL Pasini FL Baldari CT Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases Faseb J 2005, 19(6):605-607. 15677697
12. Garrett IR Gutierrez GE Rossini G Nyman J McCluskey B Flores A Mundy GR Locally delivered lovastatin nanoparticles enhance fracture healing in rats J Orthop Res 2007, 25(10):1351-1357. 10.1002/jor.20391 17506505
13. Skoglund B Aspenberg P Locally applied Simvastatin improves fracture healing in mice BMC Musculoskelet Disord 2007, 8:98. 2200653 17897477 10.1186/1471-2474-8-98
14. Skoglund B Forslund C Aspenberg P Simvastatin improves fracture healing in mice J Bone Miner Res 2002, 17(11):2004-2008. 10.1359/ jbmr.2002.17.11.2004 12412808
15. Ohnaka K Shimoda S Nawata H Shimokawa H Kaibuchi K Iwamoto Y Takayanagi R Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts Biochem Biophys Res Commun 2001, 287(2):337-342. 10.1006/bbrc.2001.5597 11554731
16. Fisher JE Rogers MJ Halasy JM Luckman SP Hughes DE Masarachia PJ Wesolowski G Russell RG Rodan GA Reszka AA Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro Proc Natl Acad Sci USA 1999, 96(1):133-138. 15105 9874784 10.1073/pnas.96.1.133
17. Jadhav SB Jain GK Statins and osteoporosis: New role for old drugs J Pharm Pharmacol 2006, 58(1):3-18. 10.1211/jpp.58.1.0002 16393459
18. Li W Cui Y Kushner SA Brown RA Jentsch JD Frankland PW Cannon TD Silva AJ The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1 Curr Biol 2005, 15(21):1961-1967. 10.1016/j.cub.2005.09.043 16271875
19. Zhu Y Romero MI Ghosh P Ye Z Charnay P Rushing EJ Marth JD Parada LF Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain Genes Dev 2001, 15(7):859-876. 312666 11297510 10.1101/gad.862101
20. Kita T Brown MS Goldstein JL Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase J Clin Invest 1980, 66(5):1094-1100. 371547 6903572 10.1172/JCI109938
21. Ratzka A Kalus I Moser M Dierks T Mundlos S Vortkamp A Redundant function of the heparan sulfate 6-O-endosulfatases Sulf1 and Sulf2 during skeletal development Dev Dyn 2008, 237(2):339-353. 10.1002/ dvdy.21423 18213582
22. Vortkamp A Lee K Lanske B Segre GV Kronenberg HM Tabin CJ Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein Science 1996, 273(5275):613-622. 10.1126/science.273.5275.613 8662546
23. Yoshitake H Rittling SR Denhardt DT Noda M Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption Proc Natl Acad Sci USA 1999, 96(14):8156-8160. 22204 10393964 10.1073/pnas.96.14.8156
24. Asou Y Rittling SR Yoshitake H Tsuji K Shinomiya K Nifuji A Denhardt DT Noda M Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone Endocrinology 2001, 142(3):1325-1332. 10.1210/en.142.3.1325 11181551
25. Yu X Chen S Potter OL Murthy SM Li J Pulcini JM Ohashi N Winata T Everett ET Ingram D Clapp WD Hock JM Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning Bone 2005, 36(5):793-802. 10.1016/j.bone.2005.01.022 15804420
26. Konishi K Nakamura M Yamakawa H Suzuki H Saruta T Hanaoka H Davatchi F Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis Am J Med Sci 1991, 301(5):322-328. 10.1097/00000441-199105000-00006 1902351
27. Weinstein RS Harris RL Hypercalcemic hyperparathyroidism and hypophosphatemic osteomalacia complicating neurofibromatosis Calcif Tissue Int 1990, 46(6):361-366. 10.1007/BF02554965 2114209
28. Kuorilehto T Poyhonen M Bloigu R Heikkinen J Vaananen K Peltonen J Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body Osteoporos Int 2005, 16(8):928-936. 10.1007/s00198-004-1801-4 15551055
29. Ben-Baruch D Ziv Y Sandbank J Wolloch Y Oncogenic osteomalacia induced by schwannoma in a patient with neurofibromatosis Eur J Surg Oncol 1994, 20(1):57-61. 8131871
30. Mundy GR Directions of drug discovery in osteoporosis Annu Rev Med 2002, 53:337-354. 10.1146/annurev.med.53.082901.104047 11818478
31. Khosravi-Far R Cox AD Kato K Der CJ Protein prenylation: Key to ras function and cancer intervention? Cell Growth Differ 1992, 3(7):461-469. 1419908
32. Elefteriou F Benson MD Sowa H Starbuck M Liu X Ron D Parada LF Karsenty G ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae Cell Metab 2006, 4(6):441-451. 10.1016/j.cmet.2006.10.010 17141628
33. Kono SJ Oshima Y Hoshi K Bonewald LF Oda H Nakamura K Kawaguchi H Tanaka S Erk pathways negatively regulate matrix mineralization Bone 2007, 40(1):68-74. 10.1016/j.bone.2006.07.024 16978937